0.05Open0.05Pre Close0 Volume54 Open Interest12.50Strike Price0.00Turnover1682.03%IV24.91%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0409Delta0.0310Gamma331.60Leverage Ratio-3.1526Theta0.0000Rho-13.57Eff Leverage0.0001Vega
Grail Stock Discussion
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet